经颈静脉肝内门体分流术后肝性脑病的研究进展

王重; 刘福全

doi:10.3969/j.issn.1001-5256.2019.12.040

经颈静脉肝内门体分流术后肝性脑病的研究进展

DOI: 10.3969/j.issn.1001-5256.2019.12.040

王重,
刘福全

首都医科大学附属北京世纪坛医院介入治疗科

基金项目:

首都卫生发展科研专项(2018-1-2081)；

详细信息

中图分类号: R575.3;R747.9
计量
- 文章访问数: 1163
- HTML全文浏览量: 20
- PDF下载量: 241
- 被引次数: 0
出版历程
- 收稿日期: 2019-07-23
- 出版日期: 2019-12-20

Research advances in hepatic encephalopathy after transjugular intrahepatic portosystemic shunt

Department of Interventional Therapy,Beijing Shijitan Hospital,Capital Medical University

Research funding:

摘要

摘要: 经颈静脉肝内门体分流术(TIPS)已成为治疗门静脉高压症相关并发症的有效手段。聚四氟乙烯覆膜支架的应用提高了分流道的通畅性,但TIPS术后发生肝性脑病仍然是一个重要的问题。阐述了TIPS术后肝性脑病的流行病学﹑发病机制﹑相关发病因素和治疗等,进一步提高对肝性脑病的认识和了解。
- 高血压,门静脉 /
- 门体分流术,经颈静脉肝内 /
- 肝性脑病
Abstract: Transjugular intrahepatic portosystemic shunt( TIPS) has become an effective method for the treatment of portal hypertension.Although the use of polytetrafluoroethylene covered stents enhances shunt patency,hepatic encephalopathy remains a significant issue after TIPS. This article reviews the epidemiology,pathogenesis,pathogenic factors,and treatment of post-TIPS hepatic encephalopathy,so as to improve the understanding and awareness of this issue.
- hypertension,portal /
- portasystemic shunt,transjugular intrahepatic /
- hepatic encephalopathy

HTML全文

参考文献(37)

[1] International Group,Chinese Society of Radiology,Chinese Medical Association. Expert consensus on transjugular intrahepatic portosystemic shunt[J]. J Clin Hepatol,2017,33(7):1218-1228.(in Chinese)中华医学会放射学分会介入学组．经颈静脉肝内门体分流术专家共识[J]．临床肝胆病杂志，2017,33(7):1218-1228.

[2] TALARI G,TALARI P,DELA CA. Hepatic encephalopathy[J]. N Engl J Med,2017,376(2):186.

[3] GAO XY,GUO CH,ZHU W,et al. Study on the abnormal thyroliberin and related factors in patients with acute hepatic failure related encephpathy of type A hepatitis and its related influencing factors[J]. J Clin Exp Med,2019,18(3):274-277.(in Chinese)高秀莹，郭彩红，朱巍，等．急性肝衰竭相关A型肝性脑病患者促甲状腺激素的异常及其相关影响因素[J]．临床和实验医学杂志，2019,18(3):274-277.

[4] Chinese Society of Hepatology,Chinese Medical Association.Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol,2018,34(10):2076-2089.(in Chinese)中华医学会肝病学分会．肝硬化肝性脑病诊疗指南[J]．临床肝胆病杂志，2018,34(10):2076-2089.

[5] TREBICKA J,BASTGEN D,BYRTUS J,et al. Smaller-diameter covered transjugular intrahepatic portosystemic shunt stents are associated with increased survival[J]. Clin Gastroenterol Hepatol,2019.[Epub ahead of print]

[6] KRAGLUND F,JEPSEN P,AMANAVICIUS N,et al. Longterm effects and complications of the transjugular intrahepatic portosystemic shunt:A single-centre experience[J]. Scand J Gastroenterol,2019,54(7):899-904.

[7] FERENCI P,LOCKWOOD A,MULLEN K,et al. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification:Final report of the working party at the 11th World Congresses of Gastroenterology,Vienna,1998[J].Hepatology,2002,35(3):716-721.

[8] VILSTRUP H,AMODIO P,BAJAJ J,et al. Hepatic encephalopathy in chronic liver disease:2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver[J]. Hepatology,2014,60(2):715-735.

[9] WEISS N,JALAN R,THABUT D. Understanding hepatic encephalopathy[J]. Intensive Care Med,2018,44(2):231-234.

[10] HE F,DAI S,XIAO Z,et al. Pathological predictors of shunt stenosis and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Biomed Res Int,2016,2016:3681731.

[11] NARDELLI S,GIOIA S,PASQUALE C,et al. Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Am J Gastroenterol,2016,111(4):523-528.

[12] WU M,SUN M. Method and research progress of non-invasive&assessment of portal vein pressure[J]. Chin J Dig Surg,2018,17(10):1055-1058.(in Chinese)吴敏，孙敏．门静脉压力无创测定的方法和研究进展[J]．中华消化外科杂志，2018,17(10):1055-1058.

[13] Chinese Portal Hypertension Diagnosis and Monitoring Study Group(CHESS); Minimally Invasive Intervention Collaborative Group,Chinese Society of Gastroenterology; Emergency Intervention Committee,Chinese College of Interventionalists,et al. Consensus on clinical application of hepatic venous pressure gradient in China(2018)[J]. J Clin Hepatol,2018,34(12):2526-2536.(in Chinese)中国门静脉高压诊断与监测研究组(CHESS)，中华医学会消化病学分会微创介入协作组，中国医师协会介入医师分会急诊介入专业委员会，等．中国肝静脉压力梯度临床应用专家共识(2018版)[J]．临床肝胆病杂志，2018,34(12):2526-2536.

[14] HE C,LV Y,WANG Z,et al. Association between nonvariceal spontaneous portosystemic shunt and outcomes after TIPS in cirrhosis[J]. Dig Liver Dis,2018,50(12):1315-1323.

[15] LV Y,HE C,WANG Z,et al. Association of nonmalignant portal vein thrombosis and outcomes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis[J]. Radiology,2017,285(3):999-1010.

[16] TRIANTAFYLLOU T,AGGARWAL P,GUPTA E,et al. Polytetrafluoroethylene-covered stent graft versus bare stent in transjugular intrahepatic portosystemic shunt:Systematic review and meta-analysis[J]. J Laparoendosc Adv Surg Tech,2018,28(7):867-879.

[17] WANG Q,LV Y,BAI M,et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding[J]. J Hepatol,2017,67(3):508-516.

[18] LUO SH,CHU JG,HUANG H,et al. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy[J].World J Gastroenterol,2019,25(9):1088-1099.

[19] MIAO TG,CHU JG,HUANG H,et al. The influence of the stent position in transjugular intrahepatic left branch of portal vein portosystemic shunt on the long-term effect[J]. J Intervent Radiol,2017,26(4):299-302.(in Chinese)苗同国，褚建国，黄鹤，等．经颈静脉肝内门静脉左支门体分流中支架位置对远期疗效的影响[J]．介入放射学杂志，2017,26(4):299-302.

[20] TSAI CF,CHEN MH,WANG YP,et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study[J]. Gastroenterology,2017,152(1):134-141.

[21] RIGGIO O,ANGELONI S,SALVATORI F M,et al. Incidence,natural history,and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts[J]. Am J Gastroenterol,2008,103(11):2738-2746.

[22] PEREIRA K,CARRION AF,SALSAMENDI J,et al. Endovascular management of refractory hepatic encephalopathy complication of transjugular intrahepatic portosystemic shunt(TIPS):Comprehensive review and clinical practice algorithm[J]. Cardiovasc Intervent Radiol,2016,39(2):170-182.

[23] COPE C,HASKAL ZJ. Judicious use of intentional reversible thrombosis of transjugular intrahepatic portosystemic shunt and renal blood flow[J]. Radiology,1995,197(3):588.

[24] JALAN R,HAYES PC. Risk of intentional reversible thrombosis of transjugular intrahepatic portosystemic shunt[J]. Radiology,1995,197(3):587.

[25] PATTYNAMA PM,WILS A,van der LINDEN E,et al. Embolization with the Amplatzer Vascular Plug in TIPS patients[J].Cardiovasc Intervent Radiol,2007,30(6):1218-1221.

[26] JOSEPH AS,SANDHU B,KHALIL A,et al. Transjugular portosystemic shunt reductions:A retrospective single-center experience[J]. J Vasc Interv Radiol,2019,30(6):876-884.

[27] PEREIRA K,CARRION AF,MARTIN P,et al. Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy[J]. Liver Int,2015,35(12):2487-2494.

[28] ZARDI EM,UWECHIE V,CACCAVO D,et al. Portosystemic shunts in a large cohort of patients with liver cirrhosis:Detection rate and clinical relevance[J]. J Gastroenterol,2009,44(1):76-83.

[29] LALEMAN W,SIMON-TALERO M,MALEUX G,et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy:A multicenter survey on safety and efficacy[J]. Hepatology,2013,57(6):2448-2457.

[30] BORENTAIN P,SOUSSAN J,RESSEGUIER N,et al. The presence of spontaneous portosystemic shunts increases the risk of complications after transjugular intrahepatic portosystemic shunt(TIPS)placement[J]. Diagn Interv Imaging,2016,97(6):643-650.

[31] WU W,HE C,HAN G. Embolization of spontaneous splenorenal shunt for after-TIPS hepatic encephalopathy in a patient with cirrhosis and variceal bleeding[J]. Hepatology,2015,61(5):1761-1762.

[32] LEE EW,SAAB S,KALDAS F,et al. Coil-Assisted Retrograde Transvenous Obliteration(CARTO):An alternative treatment option for refractory hepatic encephalopathy[J]. Am J Gastroenterol,2018,113(8):1187-1196.

[33] ZHU Y,WANG X,LUO X,et al. Balloon-Occluded Retrograde Transvenous Obliteration(BRTO)or Coil-Assisted Retrograde Transvenous Obliteration(CARTO):Which one do we choose?[J]. Am J Gastroenterol,2018,113(12):1901-1902.

[34] YOSHIDA H,MAMADA Y,TANIAI N,et al. Long-term results of partial splenic artery embolization as supplemental treatment for portal-systemic encephalopathy[J]. Am J Gastroenterol,2005,100(1):43-47.

[35] WAGURI N,HAYASHI M,YOKOO T,et al. Simultaneous combined balloon-occluded retrograde transvenous obliteration and partial splenic embolization for portosystemic shunts[J]. J Vasc Interv Radiol,2012,23(5):650-657.

[36] MACDONALD AJ,KARVELLAS CJ. Emerging role of extracorporeal support in acute and acute-on-chronic liver failure:Recent developments[J]. Semin Respir Crit Care Med,2018,39(5):625-634.

[37] XU X,GUO HJ,LI WY. Treatment options for portal hypertension in the era of liver transplantation[J]. Chin J Dig Surg,2018,17(10):992-996.(in Chinese)徐骁，郭海军，李望遥．肝移植时代门静脉高压症的治疗选择[J]．中华消化外科杂志，2018,17(10):992-996.

施引文献

资源附件(0)

访问统计